百健

Biogen Inc receives a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% premium over our quantitative fair value estimate of $220.73 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating.

The firm's valuation metrics decrease our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 1.2 falls in the top 40% compared with peers globally. The market value of equity is low relative to the business' enterprise value, suggesting the company could be buried in debt if anything goes wrong. We believe this is a sign that shares could be expensive.

Conversely, the firm's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's enterprise value to free cash flow ratio of 13.1, for example, sits in the bottom 30% globally. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.